At this year’s annual meeting of the American Society of Gene and Cell Therapy (ASGCT), French biotechnology company EG 427 will share recent advances in the development of its recombinant, ...
First patient now successfully dosed in the EG110A clinical study being conducted at four leading US institutions Phase 1b/2a study to recruit 16 patients with neurogenic detrusor overactivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results